Apollomics (APLM) News Today

Apollomics Inc. (NASDAQ: APLM) is trading higher today on heavy volume after a string of company and market events that increased investor attention. Key drivers: Nasdaq confirmed Apollomics is in compliance with continued listing requirements (removing delisting risk), the stock experienced multiple LULD trading pauses amid high intraday activity, and short interest jumped sharply in September.

• Positive Sentiment: Nasdaq confirmed Apollomics is compliant with continued listing requirements, cancelling a planned appeal hearing and ensuring the company's securities remain listed — a clear de‑risking event that can restore investor confidence and remove delisting overhang. Apollomics Announces Continued Listing on The Nasdaq Stock Market
• Neutral Sentiment: Multiple Limit Up/Limit Down (LULD) trading pauses were triggered across Oct. 15–16, indicating elevated intraday volatility and unusually high order flow — this explains intermittent halts and the large jump in traded volume but is not a directional fundamental signal on its own.
• Negative Sentiment: Short interest surged to ~75,500 shares as of Sept. 30 (about 14.0% of float), a reported ~2,696% increase from mid‑September; while the short‑interest ratio is modest (~1.5 days), the large percentage of shares sold short signals substantial bearish bets or hedging activity and adds downside pressure and volatility risk going forward.

Investor takeaway: the Nasdaq compliance news is the primary positive catalyst supporting the rally and reduced delisting risk, LULD pauses reflect heavy speculative trading, and the spike in short interest raises the potential for continued volatility (and short‑squeeze dynamics). Monitor clinical updates for vebreltinib (APL‑101) and any further regulatory or volume developments for near‑term moves.